Literature DB >> 27227354

Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.

Mohammed Ashraf1, Ahmed A R Souka2, Hassan El Kayal2, Mostafa El Manhaly2, Mohamed Hossam Abdallah2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27227354     DOI： 10.1111/aos.13111

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  3 in total

1.  Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population.

Authors:  Imoro Zeba Braimah; Winfried M Amoaku
Journal:  Eye (Lond)       Date:  2022-05       Impact factor: 4.456

2.  Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study.

Authors:  Imoro Zeba Braimah; Ernest Kenu; Kwesi N Amissah-Arthur; Stephen Akafo; Kwaku Oppong Kwarteng; Winfried M Amoaku
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

3.  Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.

Authors:  Julia de Lima Farah; Ronaldo Sano; Ieda Maria Longo Maugéri; Daniela Teixeira; Mayari Eika Ishimura; Gabriela Martins; Lycia M J Mimica; Cely Barreto da Silva; Carsten H Meyer; João Rafael de Oliveira Dias; Gabriel Costa de Andrade; Michel Eid Farah
Journal:  Int J Retina Vitreous       Date:  2018-10-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.